Averted HIV infections due to expanded antiretroviral treatment eligibility offsets risk of transmitted drug resistance: A modeling study

AIDS

Volumn 28, Issue 1, 2014, Pages 73-83

  Nichols, Brooke E ^a   Sigaloff, Kim C E ^b,c   Kityo, Cissy ^d   Mandaliya, Kishor ^e   Hamers, Raph L ^b,c   Bertagnolio, Silvia ^f   Jordan, Michael R ^g   Boucher, Charles A B ^a   Wit, Tobias F Rinke De ^b,c   Vijver, David A M C Van De ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b PharmAccess Foundation   (Netherlands)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d JOINT CLINICAL RESEARCH CENTRE   (Uganda)

^e Department of Obstetrics and Gynaecology   (Kenya)

^f WORLD HEALTH ORGANIZATION   (Switzerland)

^g TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antiretroviral treatment; Mathematical modeling; Primary HIV 1 drug resistance; Sub Saharan Africa

Indexed keywords

EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; STAVUDINE; TENOFOVIR; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AFRICA; ARTICLE; CALIBRATION; CD4 LYMPHOCYTE COUNT; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE DURATION; DISEASE RESISTANCE; DRUG TREATMENT FAILURE; EPIDEMIC; FEMALE; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; INCIDENCE; KAMPALA; KENYA; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; MOMBASA; MORTALITY; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; SEXUAL BEHAVIOR; SEXUALITY; TRANSMITTED DRUG RESISTANCE; UGANDA; VIRUS LOAD; VIRUS MUTATION; ANTIVIRAL RESISTANCE; HIV INFECTIONS; THEORETICAL MODEL; TIME; TRANSMISSION; VIROLOGY; YOUNG ADULT;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HUMANS; INCIDENCE; KENYA; MALE; MODELS, THEORETICAL; TIME FACTORS; UGANDA; YOUNG ADULT;

EID: 84892373623     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/01.aids.0000433239.01611.52     Document Type: Article

References (41)

1. WHO. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach: 2010 rev. Geneva: World Health Organization; 2010.
2. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365:493-505.
3. Hamers RL, Schuurman R, Sigaloff KC, Wallis CL, Kityo C, Siwale M, et al. Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort study. Lancet Infect Dis 2012; 12:307-317.
4. Gupta RK, Jordan MR, Sultan BJ, Hill A, Davis DH, Gregson J, et al. Global trends in antiretroviral resistance in treatmentnaive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis. Lancet 2012; 380:1250-1258.
5. Ndembi N, Hamers RL, Sigaloff KC, Lyagoba F, Magambo B, Nanteza B, et al. Transmitted antiretroviral drug resistance among newly HIV-1 diagnosed young individuals in Kampala. AIDS 2011; 25:905-910.
6. Sigaloff KC, Mandaliya K, Hamers RL, Otieno F, Jao IM, Lyagoba F, et al. Short communication: high prevalence of transmitted antiretroviral drug resistance among newly HIV type 1 diagnosed adults in Mombasa, Kenya. AIDS Res Hum Retroviruses 2012; 28:833-837.
7. Phillips AN, Pillay D, Garnett G, Bennett D, Vitoria M, Cambiano V, Lundgren J. Effect on transmission of HIV-1 resistance of timing of implementation of viral load monitoring to determine switches from first to second-line antiretroviral regimens in resource-limited settings. AIDS 2011; 25:843-850.
8. Baggaley RF, Garnett GP, Ferguson NM. Modelling the impact of antiretroviral use in resource-poor settings. PLoS Med 2006; 3:e124.
9. Wilson DP, Kahn J, Blower SM. Predicting the epidemiological impact of antiretroviral allocation strategies in KwaZulu-Natal: the effect of the urban-rural divide. Proc Natl Acad Sci USA 2006; 103:14228-14233.
10. Vardavas R, Blower S. The emergence of HIV transmitted resistance in Botswana: 'when will the WHO detection threshold be exceeded?'. PLoS One 2007; 2:e152.
11. Hamers RL, Wallis CL, Kityo C, Siwale M, Mandaliya K, Conradie F, et al. HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. Lancet Infect Dis 2011; 11:750-759.
12. WHO. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach, 2006 revision. Geneva, Switzerland: World Health Organization; 2006, (http://www.who.int/hiv/pub/ guidelines/artadultguidelines. pdf).
13. DHHS. Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services 2012; http://www.aidsinfo. nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf. [Accessed 17 July
14. 2012] 14. Hollingsworth TD, Anderson RM, Fraser C. HIV-1 transmission, by stage of infection. J Infect Dis 2008; 198:687-693.
15. Ruark A, Shelton JD, Halperin DT, Wawer MJ, Gray RH. Universal voluntary HIV testing and immediate antiretroviral therapy. Lancet 2009; 373:1078[author reply 1080-1071].
16. Pilcher CD, Joaki G, Hoffman IF, Martinson FE, Mapanje C, Stewart PW, et al. Amplified transmission of HIV-1: comparison of HIV-1 concentrations in semen and blood during acute and chronic infection. AIDS 2007; 21:1723-1730.
17. Lodi S, Phillips A, Touloumi G, Geskus R, Meyer L, Thiebaut R, et al. Time from human immunodeficiency virus seroconversion to reaching CD4R cell count thresholds
18. Reynolds SJ, Makumbi F, Nakigozi G, Kagaayi J, Gray RH, Wawer M, et al. HIV-1 transmission among HIV-1 discordant couples before and after the introduction of antiretroviral therapy. AIDS 2011; 25:473-477.
19. Landier J, Akonde A, Pizzocolo C, Haidara I, Drabo M, Pizarro L, et al. Switch to second-line ART in West African routine care: incidence and reasons for switching. AIDS Care 2011; 23: 75-78.
20. Garnett GP, Anderson RM. Factors controlling the spread of HIV in heterosexual communities in developing countries: patterns of mixing between different age and sexual activity classes. Philos Trans R Soc Lond B Biol Sci 1993; 342:137-159.
21. Rose KA, Smith E, Gardner R, Brenkert A, Bartell S. Parameter sensitivities, Monte Carlo Filtering, and model forecasting under uncertainty. J Forecast 1991; 10:117-133.
22. STD/AIDS Control Programme. The HIV/AIDS Epidemiological Surveillance Report 2010. Kampala, Uganda: Ministry of Health; 2010.
23. National AIDS and STI Control Program. Sentinel surveillance for HIV and Syphilis among pregnant women, 2010. Nairobi: NASCOP; 2010.
24. Venables WN, Ripley BD. Chapter 9: tree-based methods. In: Venables WN, Ripley BD,editors. Modern Applied statistics with S. 4th ed. New York: Springer; 2002.
25. Therneau TM, Atkinson EJ. An introduction to recursive partitioning using the RPART routines.Mayo Foundation; 1997, 251, 258.
26. De Luca A. The impact of resistance on viral fitness and its clinical implications. In: Geretti AM. editor. Antiretroviral resistance in clinical practice London: Mediscript; 2006. Chapter 12.
27. Nijhuis M, Deeks S, Boucher C. Implications of antiretroviral resistance on viral fitness. Curr Opin Infect Dis 2001; 14:23-28.
28. Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C, Wabwire-Mangen F, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000; 342:921-929.
29. Xu HT, Martinez-Cajas JL, Ntemgwa ML, Coutsinos D, Frankel FA, Brenner BG, Wainberg MA. Effects of the K65R and K65R/M184V reverse transcriptase mutations in subtype C HIV on enzyme function and drug resistance. Retrovirology 2009; 6:14.
30. Smith RJ, Okano JT, Kahn JS, Bodine EN, Blower S. Evolutionary dynamics of complex networks of HIV drug-resistant strains: the case of San Francisco. Science 2010; 327:697-701.
31. Cong ME, Heneine W, Garcia-Lerma JG. The fitness cost of mutations associated with human immunodeficiency virus type 1 drug resistance is modulated by mutational interactions. J Virol 2007; 81:3037-3041.
32. Armstrong KL, Lee TH, Essex M. Replicative fitness costs of nonnucleoside reverse transcriptase inhibitor drug resistance mutations on HIV subtype C. Antimicrob Agents Chemother 2011; 55:2146-2153.
33. WHO. Rapid advice: antiretroviral therapy for HIV infection in adults and adolescents. Geneva, Switzerland: World Health Organization; 2009.
34. van de Vijver DA, Wensing AM, Angarano G, Asjo B, Balotta C, Boeri E, et al. The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes. J Acquir Immune Defic Syndr 2006; 41:352-360.
35. Jain V, Sucupira MC, Bacchetti P, Hartogensis W, Diaz RS, Kallas EG, et al. Differential persistence of transmitted HIV-1 drug resistance mutation classes. J Infect Dis 2011; 203:1174-1181.
36. Weidle PJ, Malamba S, Mwebaze R, Sozi C, Rukundo G, Downing R, et al. Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance. Lancet 2002; 360:34-40.
37. Abbas UL, Glaubius R, Mubayi A, Hood G, Mellors JW. Antiretroviral therapy and preexposure prophylaxis: combined impact on HIV-1 transmission and drug resistance in South Africa. J Infect Dis 2013; 208:224-234.
38. Sabin CA, Smith CJ, Youle M, Lampe FC, Bell DR, Puradiredja D, et al. Deaths in the era of HAART: contribution of late presentation, treatment exposure, resistance and abnormal laboratory markers. AIDS 2006; 20: 67-71.
39. Hogg RS, Bangsberg DR, Lima VD, Alexander C, Bonner S, Yip B, et al. Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART. PLoS Med 2006; 3:e356.
40. UK National Guidelines for HIV Testing 2008. http://www. bhiva.org/files/file1031097.pdf. British HIV Association; 2008.
41. Nichols BE, Boucher CA, van de Vijver DA. HIV testing and antiretroviral treatment strategies for prevention of HIV infection: impact on antiretroviral drug resistance. J Intern Med 2011; 270:532-549.